Update on mantle cell lymphoma
K Maddocks - Blood, The Journal of the American Society of …, 2018 - ashpublications.org
Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma that is most
commonly treated with combination chemo-immunotherapy at diagnosis because of the …
commonly treated with combination chemo-immunotherapy at diagnosis because of the …
CAR T-cell therapy for B-cell lymphoma
N Denlinger, D Bond, S Jaglowski - Current problems in cancer, 2022 - Elsevier
Chimeric antigen receptor-modified (CAR) T-cell therapy targeting CD19 has revolutionized
the treatment of relapsed or refractory B-cell lymphomas. Based on unprecedented …
the treatment of relapsed or refractory B-cell lymphomas. Based on unprecedented …
[HTML][HTML] Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study
Purpose Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen
receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell …
receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell …
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Summary Background Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficacious in
multiple B-cell malignancies, but patients discontinue these agents due to resistance and …
multiple B-cell malignancies, but patients discontinue these agents due to resistance and …
KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma
Background Patients with relapsed or refractory mantle-cell lymphoma who have disease
progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy …
progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy …
Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma
PURPOSE Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase
inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent …
inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent …
Clinical cancer advances 2021: ASCO's report on progress against cancer
SM Smith, K Wachter, HA Burris III… - Journal of Clinical …, 2021 - ascopubs.org
Executive Summary Clinical Cancer Advances 2021: ASCO's Report on Progress Against
Cancer highlights the most important clinical research advances of the past year and …
Cancer highlights the most important clinical research advances of the past year and …
[HTML][HTML] Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy
TA Eyre, HS Walter, S Iyengar, G Follows, M Cross… - …, 2019 - ncbi.nlm.nih.gov
Mantle cell lymphoma (MCL), an aggressive B-cell malignancy accounting for 6% of non-
Hodgkin lymphomas, remains incurable with standard therapy. Despite the approval of …
Hodgkin lymphomas, remains incurable with standard therapy. Despite the approval of …
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
Introduction: The therapeutic options for mantle cell lymphoma (MCL) include traditional
chemo-immunotherapy for newly diagnosed cases, and targeted treatments including the …
chemo-immunotherapy for newly diagnosed cases, and targeted treatments including the …
[HTML][HTML] Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
N Jain, M Mamgain, SM Chowdhury, U Jindal… - Journal of Hematology & …, 2023 - Springer
Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2–6% of all
NHLs and characterized by overexpression of cyclin D1. The last decade has seen the …
NHLs and characterized by overexpression of cyclin D1. The last decade has seen the …